Home | PHARMAC
Home | PHARMAC
  • Website
  • Application Tracker
  • Schedule
  • About PHARMAC
    • About PHARMAC
    • Your guide to PHARMAC
    • Our people
    • Careers at PHARMAC
    • Expert advice
    • PHARMAC's performance
    • Operating policies and procedures
    • Year in review 2018
    • Strategies
  • Medicines
    • Medicines
    • How medicines are funded
    • Medicines information
    • My medicine or medical device has changed
    • Your health
    • Hospital pharmaceuticals
    • New medicines – from development to funding
    • Equity
  • Hospital devices
    • Hospital devices
    • Feedback on managing fairer access to hospital medical devices
    • What's happening in each category?
    • About our role in device management
    • Device Advice
  • News (current)
  • Te Whaioranga
    • Te Whaioranga
    • Te Whaioranga 2013 - 2023: Māori Responsiveness Strategy
    • Whānau Ora
    • He Rongoā Pai, He Oranga Whānau
    • Scholarships
    • Hauora Arotahi - Māori health areas of focus
    • Māori Responsiveness Team
    • One Heart Many Lives
  • Pacific
    • Pacific
    • Pacific responsiveness strategy 2017-2026
    • Stage one: Pacific Responsiveness Strategy
  • Tools & resources
    • Tools & resources
    • Pharmaceutical Schedule
    • Annual Procurement Plan
    • Forms
    • Research
    • Print and PDF resources
    • Glossary
    • PHARMAC labelling preferences for prescription pharmaceuticals
  • Information for…

News

  • Media releases
  • Notifications
  • Consultations
  • Tenders
  • RFPs
  • OIA responses

News

Consultations

Proposal to widen access to levonorgestrel intrauterine system in DHB hospitals

10/10/2013

This proposal would result in the restrictions on use of levonorgestrel IUS being widened to include endometriosis, as well as amending the restriction relating to use in heavy menstrual bleeding in hospital only. Closes: Thursday, 24 October 2013.

Consultations

Proposal relating to the listing of ethinyloestradiol 20 mcg with levonorgestrel 100 mcg and ethinyloestradiol 30 mcg with levonorgestrel 150 mcg tablets

08/10/2013

PHARMAC is seeking feedback on a proposal relating to a provisional agreement with Actavis New Zealand Ltd for the oral contraceptives ethinyloestradiol 20 mcg with levonorgestrel 100 mcg and ethinyloestradiol 30 mcg with levonorgestrel 150 mcg. Closed: Tuesday, 22 October 2013.

Consultations

Proposal to amend the Practitioner’s Supply Order rules relating to certain antibiotics for rheumatic fever prevention

08/10/2013

PHARMAC is seeking feedback on a proposal to amend the Pharmaceutical Schedule General Rules regarding a Practitioner’s Supply Order (PSO) in relation to the provision of certain antibiotics for the national Rheumatic Fever Prevention Programme (RFPP). Closes: 22 October 2013.

RFPs

RFP - Supply of somatropin

08/10/2013

PHARMAC invites proposals for the supply of somatropin in New Zealand. Closed.

RFPs

RFP - Radiological contrast media

02/10/2013

PHARMAC invites proposals for the supply of Radiological Contrast Media in New Zealand. Closed.

Notifications

September 2013 tender notification

30/09/2013

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2011/12 Invitation to Tender, dated 1 November 2011 and the 2012/13 Invitation to Tender, dated 31 October 2012.

Consultations

Proposal relating to the listing of haemophilia treatments

26/09/2013

PHARMAC is seeking feedback on a proposal to fund a number of haemophilia treatments. Closed: Thursday, 10 October 2013.

Media releases

Easier access to funded enzyme replacement therapy

20/09/2013

PHARMAC is providing greater funded access to the expensive enzyme replacement therapy imiglucerase (Cerezyme), mainly expanding its use in children.

Consultations

Proposal to widen hospital funding restrictions for rituximab

13/09/2013

PHARMAC seeks feedback on a proposal to fund rituximab for more indications in hospitals. Closed: Monday, 30 September 2013.

Notifications

Approval of proposal to fund riluzole for amyotrophic lateral sclerosis (motor neurone disease)

11/09/2013

PHARMAC is pleased to announce the approval of an agreement to fund riluzole (Rilutek) for the treatment of amyotrophic lateral sclerosis (ALS, also known as motor neurone disease) from 1 October 2013, subject to some restrictions.

Notifications

August tender notification

30/08/2013

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2012/13 Invitation to Tender, dated 31 October 2012.

RFPs

ROI - Wound care products

23/08/2013

PHARMAC invites Registrations of Interest (ROIs) for listing agreements for the supply of Wound Care Products via listing on the Pharmaceutical Schedule to District Health Board hospitals from parties who are able to supply or procure the supply of the Wound Care Products. Closed.

Media releases

Four students receive pharmacy scholarships

22/08/2013

An outstanding calibre of applications has seen the Hiwinui Heke pharmacy scholarships shared among four Māori pharmacy students this year.

Consultations

Proposals for influenza vaccine

20/08/2013

PHARMAC is seeking feedback on a proposal to list two brands of influenza vaccine in the Pharmaceutical Schedule for the 2014, 2015, and 2016 influenza seasons. Closed: 4 pm, Tuesday, 3 September 2013.

Notifications

Approval of proposal to amend the definition of Specialist within the Pharmaceutical Schedule

16/08/2013

PHARMAC is pleased to announce the approval of a proposal to amend the definition of the term Specialist within the Pharmaceutical Schedule.

Notifications

Listing of alternate brands of enalapril maleate tablets

12/08/2013

Due to a pharmacy level recall of m-Enalapril tablets certain alternative products will be listed fully subsidised in the Pharmaceutical Schedule from 12 August 2013.

Notifications

Approval of proposal to widen access to imiglucerase for type 1 and type 3 Gaucher disease

09/08/2013

PHARMAC is pleased to announce the approval of a proposal to widen access to imiglucerase (Cerezyme) from 1 September 2013.

Notifications

Approval of decisions involving boceprevir and pegylated interferon with/without ribavirin

09/08/2013

PHARMAC is pleased to announce the approval of an agreement for the listing of boceprevir (Victrelis), and to amend the listing of pegylated interferon with/without ribavirin (Pegasys and Pegasys RBV Combination Pack).

Notifications

Approval of proposal to remove the Special Authority from Arrow-Venlafaxine XR

09/08/2013

PHARMAC is pleased to announce the approval of an agreement to remove the Special Authority and hospital restrictions from the Arrow-Venlafaxine XR brand of venlafaxine from 1 September 2013, in conjunction with a price decrease.

Consultations

Proposal to list riluzole for the treatment of amyotrophic lateral sclerosis (motor neurone disease)

08/08/2013

PHARMAC seeks feedback on a provisional agreement to fund riluzole (Rilutek) for the treatment of amyotrophic lateral sclerosis (ALS, also known as motor neurone disease). Closed: 5pm, Thursday, 22 August 2013.

  • 1
  • ...
  • 56
  • 57
  • 58
  • 59
  • 60
  • ...
  • 63

Newsletters

Make our website better – take a short survey

Device Advice: Your update on PHARMAC’s Hospital Medical Devices programme.


 PHARMACnz Twitter    PHARMACnz Facebook    PHARMAC in LinkedIn


Media queries

For media queries, contact:

021 863 342

media@pharmac.govt.nz

Media phone is monitored 9am–5pm weekdays

About this site

  • Sitemap
  • Copyright
  • Disclaimer
  • Privacy statement
  • Website changes
  • About this site

Contact

  • Contact us
  • Twitter - PHARMACnz
  • Facebook - PHARMACnz
  • YouTube - PHARMACgovtnz
  • LinkedIn - Pharmaceutical Management Agency (PHARMAC)
  • Careers
  • Newsfeed
  • Subscribe

Back to top

New Zealand Government